| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Anacardic Acid (Hydroginkgolic acid), a natural product isolated from cashew nut shell liquid, is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases, which also has antibacterial activity, antimicrobial activity, prostaglandin synthase inhibition, and tyrosinase and lipoxygenase inhibition. Anacardic acid regulates the activity and expression of several other crucial enzymes including NFκB kinase, lipoxygenase (LOX-1), xanthine oxidase, tyrosinase and ureases. Therefore, this compound exerts anti-oxidation, anti-inflammation and anti-tumor activities in vitro and in vivo.
| ln Vitro |
Histone acetyltransferase anacardic acid (IC50 of ~8.5 μM and ~5 μM, respectively) inhibits the HAT activities of p300 and PCAF [1]. Hyphalite growth is inhibited by anacardic acid (300 μM). In M, anacardic acid (50 μM) causes apoptosis-like traits. oryzae; caspase has no bearing on its function. Mitochondrial potential is lost when exposed to anacardic acid (1–80 μM). Antioxidant action is demonstrated by anacardic acid (1-60 μM) in M. oryzae.
|
||
|---|---|---|---|
| ln Vivo |
Anacardic acid (5 mg/kg, ip) attenuates HAT binding to the MEF2A promoter and rescues phenylephrine-induced H3K9ac hyperacetylation in C57BL/6 mice. Anacardic Acid inhibits the transcription levels of MEF2A and cardiac development-related downstream genes, attenuates the protein overexpression of cardiac downstream genes caused by phenylephrine, reverses and attenuates cardiac hypertrophy in the hearts of mice exposed to phenylephrine, and attenuates left ventricular pressure and improve cardiac function in mice with cardiac hypertrophy [2].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Anacardic acid is a hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities. It has a role as an EC 2.3.1.48 (histone acetyltransferase) inhibitor, an apoptosis inducer, a neuroprotective agent, an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor, an anticoronaviral agent, an antibacterial agent, an anti-inflammatory agent and a plant metabolite. It is a hydroxybenzoic acid and a hydroxy monocarboxylic acid. It is functionally related to a salicylic acid.
Anacardic acid has been reported in Ozoroa insignis, Knema elegans, and other organisms with data available. |
| Molecular Formula |
C22H36O3
|
|
|---|---|---|
| Molecular Weight |
348.52
|
|
| Exact Mass |
348.266
|
|
| CAS # |
16611-84-0
|
|
| Related CAS # |
|
|
| PubChem CID |
167551
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.0±0.1 g/cm3
|
|
| Boiling Point |
474.8±33.0 °C at 760 mmHg
|
|
| Melting Point |
90-91℃
|
|
| Flash Point |
255.1±21.9 °C
|
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
|
| Index of Refraction |
1.515
|
|
| LogP |
9.96
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
15
|
|
| Heavy Atom Count |
25
|
|
| Complexity |
329
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
ADFWQBGTDJIESE-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C22H36O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(23)21(19)22(24)25/h15,17-18,23H,2-14,16H2,1H3,(H,24,25)
|
|
| Chemical Name |
2-Hydroxy-6-pentadecyl-benzoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (28.69 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.17 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8693 mL | 14.3464 mL | 28.6928 mL | |
| 5 mM | 0.5739 mL | 2.8693 mL | 5.7386 mL | |
| 10 mM | 0.2869 mL | 1.4346 mL | 2.8693 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA